Owing to a typesetting error, the last line of the ®gure legends for Figures 1 ± 4 were missing in the above paper. The full ®gure legends are reproduced below. Oncogene (2002) 21, 2446 ã 2002 Nature Publishing Group All rights reserved 0950 ± 9232/02 $25.00 www.nature.com/onc Figure 2 (a) Suppression of nocodazole-induced MPF activity by either CK2 antisense or a speci®c inhibitor of p38. HeLa cells were synchronized at G1-S by double thymidine block and either collected (control) or released into cell cycle. After release, the cells were incubated with or without nocodazole (400 ng/ml). In some experiments SB203580 (20 mM) or DRB (20 mM) was added 2 h prior to nocodazole treatment. Cell lysates were then prepared and histone H1 phosphotransferase activities were measured. (b) cdc2 activity is downstream to CK2 and p38 MAPK. Proteins were immunoprecipitated with anti-cdc2 antibody and its phosphotransferase activity was assayed toward histone H1. (c) Activation of CK2 in nocodazole-arrested cells is dependent on p38 MAP kinase. CK2 protein in cell lysates, prepared from the above treatment, was immunoprecipitated with monoclonal antiCK2a antibody and assayed for phosphotransferase activity towards the CK2 speci®c substrate RRADDSDDDDD. The lower panel shows equal amounts of CK2 protein were immunoprecipitated. (d) CK2 is the major kinase phosphorylating p53 at serine 392. Cell lysates from the above treatment were immunoblotted with phospho antibodies to p53 (serine 392) and p38a. (e) p38 protein was immunoprecipitated with anti-p38a antibody and assayed for phosphotransferase activity toward activating transcription factor 2 (ATF2). The lower panel shows equal amount of p38 protein was immunoprecipitated. All of these experiments were repeated at least three times with similar results 
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